Vivos Therapeutics VVOS 深 沪
等待开盘 07-23 09:30:00 美东时间
0.404
-0.011
-2.60%
华盛通- 最 高0.4164
- 今 开0.41
- 成交量 12.50万股
- 最 低 0.4037
- 昨 收 0.4148
- 总市值 5613.4184
- 52周最高 5.21
- 市盈率 静 --
- 换手率 899.71%
- 52周最低 0.383
- 委 比 -71.43%
- 总股本 1.39万
- 历史最高 360.25
- 量 比 1.07
- 振 幅 3.06%
- 历史最低 0.383
- 每 手 1
- 风险率 1.35%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Vivos Therapeutics Announces Its Treatment With ITS FDA-Cleared Vida Oral Appliance Demonstrates Enhancement In Insomnia Severity In 100% Of Patients In Trial
Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical device and healthcare services company focused on the treatment of breathing‑related sleep disorders such as obstructive sleep apnea (OSA), insomnia, and associated chronic health conditions, today announced compell...
06-30 20:47
Vivos Therapeutics Extends Debt-for-Equity Conversion Timeline
Vivos Therapeutics ( ($VVOS) ) has issued an announcement. On June 5, 2026, Viv...
06-26 05:49
Streeterville Extends Strategic Financing Deal With Streeterville Through August 31, Reaffirming Plan To Convert Up To $4.5M Debt Into Preferred And Common Stock
Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including mild-to-severe obstructive sleep apnea ("OSA"), today announce...
06-22 20:35
Vivos Therapeutics extends Streeterville deal to convert up to $4.5 million debt into equity
Vivos Therapeutics extends Streeterville deal to convert up to $4.5 million debt into equity Vivos Therapeutics extended its strategic financing agreement with Streeterville Capital through Aug. 31, 2026. Streeterville reaffirmed plans to convert up to USD 4.5 million of debt into perpetual, non-con
06-22 20:30
Vivos Therapeutics Forms AIM Florida Sleep Care Venture
Vivos Therapeutics ( ($VVOS) ) just unveiled an update. On June 10, 2026, Vivos...
06-16 18:43
Vivos Therapeutics Announces Intent To File Registration For Proposed Rights Offering
Key Terms of the Proposed Rights Offering Exercise price: Each right is expected to entitle the holder to purchase one share of Vivos common stock at an exercise price that is the greater of $1.25 per share or 20% above the market price on the day before the record date as defined above. The final e...
06-11 20:36
美股大行评级 | 绩后暴跌，博通仍获11家大行上调目标价；CrowdStrike获21家大行集体上调目标价；Netskope、Veeva Systems惨遭多家大行下调目标价
今日重点评级关注：Ascendiant Capital：维持Vivos Therapeutics"买入"评级，目标价从3美元升至3.1美元；富国银行：维持Veeva Systems"超配"评级，目标价从317美元升至320美元
06-05 11:33
CrowdStrike To Surge Nearly 25%? Here Are 10 Notable Analyst Calls From Thursday
Top Wall Street analysts updated ratings on CRWD, OLLI, XPO, SHAK, UNH, PVH, VVOS, and SYRE. See analyst ratings page for full details.
06-04 20:40
Ascendiant Capital Maintains Buy on Vivos Therapeutics, Raises Price Target to $3.1
Ascendiant Capital analyst Lucas Ward maintains Vivos Therapeutics (NASDAQ:VVOS) with a Buy and raises the price target from $3 to $3.1.
06-04 17:52
Vivos Therapeutics Balances Rapid Growth With Cash Strain
Vivos Therapeutics, Inc. (($VVOS)) has held its Q1 earnings call. Read on for t...
05-23 08:13
